Sanofi Genzyme News |

Featured Press Releases

February 7, 2019
Sanofi announces additional data on avalglucosidase alfa in Pompe disease
Results from multiple studies of the investigational therapy avalglucosidase alfa in patients with Pompe disease were presented this week during the 15th Annual WORLDSymposium™ in Orlando, Florida. Pompe disease is a progressive, debilitating and often fatal neuromuscular disease that affects an estimated...
February 6, 2019
FDA approves Cablivi® (caplacizumab-yhdp), the first Nanobody®-based medicine, for adults with acquired thrombotic thrombocytopenic purpura (aTTP)
The U.S. Food and Drug Administration (FDA) has approved Cablivi® (caplacizumab-yhdp) in combination with plasma exchange and immunosuppression for the treatment of acquired thrombotic thrombocytopenic purpura (aTTP) in adults. Cablivi is the first FDA approved therapy specifically indicated for the...
February 5, 2019
Isatuximab Phase 3 trial meets primary endpoint of prolonging progression free survival in patients with relapsed/refractory multiple myeloma
The pivotal Phase 3 trial of isatuximab in patients with relapsed/refractory multiple myeloma met the primary endpoint of prolonging progression free survival in patients treated with isatuximab in combination with pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone alone...
January 30, 2019
Sanofi Presents Research Advances in Rare Genetic Diseases at 15th Annual WORLDSymposium™ 2019
Continued research and development is critical to advancing care for people with rare diseases who have a significant need for earlier diagnosis, better disease management opportunities, and new treatment options. Sanofi Genzyme, the specialty care global business unit of Sanofi, has been a pioneer in rare...

Leadership

Bill Sibold
Executive Vice President and Head of Sanofi Genzyme
Bill joined Sanofi Genzyme in 2011 as Senior Vice President and Head of Multiple Sclerosis, and oversaw the successful launches of its two MS treatments. As Head of Sanofi Genzyme, he leads the business’s efforts to maintain its leadership in rare diseases while continuing to grow in multiple sclerosis, oncology and immunology. More...

Tweets

RT @BioBall_MA: When it comes to fundraising, no one can beat @SanofiGenzyme team member @Heather87020356! She is on a roll! Thank… https://t.co/0iFNDINDqU-17 hours 9 min ago

After two of her three children were diagnosed with GM1 (GM1 gangliosidosis), Marilee Leishman became active with t… https://t.co/ZmjIyRZPwm-20 hours 44 min ago

Our #RareBloodDisorder’s Head of Global Public Affairs, Simone Azevedo, enjoyed connecting with @ApmpsVIDA's, Regin… https://t.co/XvOZzVUI7S-1 day 9 hours ago

@staceyvogl @SanofiUS Hi Stacey - I'd be happy to assist you. However, I have not received a PM from you. Please… https://t.co/uwgLzO4uVF-1 day 10 hours ago

@staceyvogl @SanofiUS Hi - Thanks for your message. Please PM us so I can appropriately direct your question to our Medical Director.-1 day 14 hours ago

Search Newsroom

Featured Press Releases

Featured Videos

Leadership

Media Resources

Tweets

Social Media